Teva Plots 16 Complex Launches To Weather US Revlimid Storm In 2026
Market Spooked By 2025 Outlook, As Teva Continues Hearty Pipeline Investments
Teva will look to its continued investments in complex generics and biosimilars to support continued top-line growth in 2025 and 2026, as the Israeli firm discussed during a busy year-end earnings call.
